{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-008777","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.578872+00:00","generated_at":"2026-05-24T08:48:05.094914+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NRx Pharma posts FY2024 operating loss of $18.5M; NDA filings for ketamine and bipolar drug anticipated in 2025","bullets":["Q4 2024 operating loss $2.4M, down 45% YoY; FY2024 operating loss $18.5M vs $27.8M in 2023.","Received non-binding terms for NRX-100 license with >$300M milestones plus double-digit royalties.","Initiated NDA for NRX-100 (IV ketamine) and plans NDA for NRX-101 (bipolar depression); both target PDUFA dates before Dec 31, 2025.","HOPE Therapeutics signed LOIs to acquire three precision psychiatry centers; negotiating for six more; BTIG engaged as advisor.","Cash $1.4M at Dec 31, 2024; raised $8.5M in Jan 2025; management expects sufficient cash through end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-008777","json":"https://secwatch.observer/filing/0001437749-25-008777.json","markdown":"https://secwatch.observer/filing/0001437749-25-008777.md","text":"https://secwatch.observer/filing/0001437749-25-008777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/0001437749-25-008777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/nrxp20250319_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:48:05.094914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}